See Graham's ranking
4.0
The company was formed through the separation of Johnson & Johnson’s consumer products division, resulting in the consolidation of a new, standalone entity. Following the separation and listing, the organization directed its strategy toward operational flexibility, distinguishing its consumer activities from the pharmaceutical and medical-devices segments of its former parent company.
The creation of Kenvue was primarily motivated by Johnson & Johnson’s objective to streamline its corporate structure, enabling the new entity to concentrate on managing and expanding its portfolio of consumer brands.
As an independent company, Kenvue operates in the global market for health and personal-care products. Its portfolio includes well-established brands in personal care, hygiene, and over-the-counter health, such as Neutrogena, Listerine, Tylenol, Band-Aid, Johnson’s Baby, and Aveeno.
These products serve multiple segments, including oral care, skin care, pain management, and infant care, positioning the company among the global leaders in consumer health goods. Kenvue operates in more than 100 countries, with significant presence in North America, Europe, and Asia.
In addition to direct operations across several markets, the company relies on distribution networks and local partnerships to expand product reach in strategic regions. Kenvue competes with multinational corporations such as Procter & Gamble, Unilever, and Colgate-Palmolive, as well as regional and private-label brands that share shelf space in retail and e-commerce channels.
Kenvue's shares are listed on Nasdaq under the ticker KVUE.
History and Foundation
Kenvue Inc. was officially created in 2022 in the United States, following Johnson & Johnson’s strategic decision to separate its consumer-goods operations. During the initial months, the company focused on structuring its independent operations, implementing its own governance framework, autonomous financial processes, and commercial strategies aligned with its new market positioning.
The initial public offering (IPO) took place in May 2023. From that point forward, innovation in personal-care products became a core priority, supported by significant investments in digital expansion and e-commerce development to enhance consumer access.
Growth strategies were implemented to strengthen global presence, leveraging the heritage of iconic brands inherited from Johnson & Johnson. Resources were allocated to research and development, aiming to improve product formulations and meet rising demand for sustainable and innovative consumer-health solutions.
Between 2023 and 2024, progress in sustainability targets drove new initiatives, including reducing plastic waste and expanding the use of natural ingredients in formulations. The adoption of environmental practices aligned with global trends in conscious consumption formed part of the company’s effort to meet sector expectations.
Operational independence enabled a more agile response to regulatory changes and evolving consumer preferences. Investments in emerging technologies and digital strategies were directed toward enhancing processes and expanding presence in the personal-care segment.
Additional Information
The Company Kenvue Inc. (United States), is listed on Nasdaq with a market cap of $ 32.47 Billions, having an equity of $ 10.63 Billions.
The Company is listedthe in the sector of Others and categorized in industry of Others.
In the last 12 months the Company had a revenue of $ 15.01 Billions, which generated a profit in the amount of $ 1.43 Billion.
As for its main indicators, the Company has a P/E ratio of 22.66, a P/BV ratio of 3.05 and in the last 12 months the dividend yield of KVUE was at 4.87%.
The Company is traded internationally through the ticker KVUE.
